A Test-based strategy is more cost effective than empiric dose escalation for patients with crohn's disease who lose responsiveness to infliximab

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 6, 2013, Pages 654-666

  Velayos, Fernando S ^a   Kahn, James G ^b   Sandborn, William J ^c   Feagan, Brian G ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Algorithm.; Anti TNF Agent; Decision Analysis; Failed Therapy

Indexed keywords

INFLIXIMAB; NATALIZUMAB;

ARTICLE; BIOLOGICAL THERAPY; COLONOSCOPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CROHN DISEASE; DRUG DOSE ESCALATION; HUMAN; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; REMISSION; TREATMENT RESPONSE;

ALGORITHMS; ANTIBODIES, MONOCLONAL; COSTS AND COST ANALYSIS; CROHN DISEASE; DECISION SUPPORT TECHNIQUES; HUMANS; IMMUNOLOGIC FACTORS; TREATMENT FAILURE;

EID: 84878142925     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.035     Document Type: Article

References (39)

1. Gisbert J.P., Panés J. Loss of response and requirement of IFX dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104:760-767.
2. Ben-Horin S., Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011, 33:987-995.
3. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum IFX to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
4. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of IFX in Crohn's disease. N Engl J Med 2003, 348:601-608.
5. Afif W., Loftus E.V., Faubion W.A., et al. Clinical utility of measuring IFX and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
6. D'Haens G.R., Panaccione R., Higgins P.D., et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011, 106:199-212. quiz 213.
7. Spiegel B., Harris L., Lucak S., et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF cohort. Am J Gastroenterol 2009, 104:1984-1991.
8. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with IFX: a randomized trial. Ann Intern Med 2007, 146:829-838.
9. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of IFX in Crohn's disease. Gastroenterology 2004, 126:402-413.
10. Shiroiwa T., Sung Y.K., Fukuda T., et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ 2010, 19:422-437.
11. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
12. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
13. Colombel J.F., Sandborn W.J., Reinisch W., et al. IFX, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
14. Sandborn W.J., Schreiber S., Feagan B.G., et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011, 9:670-678. e3.
15. Targan S.R., Feagan B.G., Fedorak R.N., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007, 132:1672-1683.
16. Katz L., Gisbert J.P., Manoogian B., et al. Doubling the IFX dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012, 18:2026-2033.
17. Allez M., Vermeire S., Mozziconacci N., et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010, 31:92-101.
18. Sandborn W.J., Abreu M.T., D'Haens G., et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to IFX. Clin Gastroenterol Hepatol 2010, 8:688-695e2.
19. FDA drug safety communication: new risk factor for progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab), 2012 Administration UFaD. http://www.fda.gov/drugs/drugsafety/ucm288186.htm.
20. Solem C.A., Loftus E.V., Tremaine W.J., et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
21. Colombel J.F., Solem C.A., Sandborn W.J., et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006, 55:1561-1567.
22. Vande Casteele N., Ballet V., Van Assche G., et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of IFX and adalimumab treatment. Gut 2012, 61:321. author reply 322.
23. Study investigating tailored treatment with IFX for active Crohn's disease (TAILORIX) Digestives GdETdAI. http://clinicaltrials.gov/ct2/show/NCT01442025.
24. Ordás I., Mould D.R., Feagan B.G., et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012, 91:635-646.
25. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
26. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance IFX for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
27. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
28. Regueiro M., Schraut W., Baidoo L., et al. IFX prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450. e1; quiz 716.
29. Sorrentino D., Terrosu G., Paviotti A., et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by IFX-a pilot study. Dig Dis Sci 2012, 57:1341-1348.
30. Sandborn W.J., Schreiber S., Hanauer S.B., et al. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 study. Clin Gastroenterol Hepatol 2010, 8:696-702. e1.
31. Kaplan G.G., Hur C., Korzenik J., et al. IFX dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007, 26:1509-1520.
32. Silverstein M.D., Loftus E.V., Sandborn W.J., et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999, 117:49-57.
33. Drug topics red book 2010, PDR Network, LLC.
34. Ananthakrishnan A.N., Hur C., Juillerat P., et al. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. Am J Gastroenterol 2011, 106:2009-2017.
35. Diagnostics PTa. Notification of patient financial responsibility for Prometheus testing. 2012 http://www.prometheuslabs.com/Resources/Billing/Notification.pdf.
36. Levesque B.G., Cipriano L.E., Chang S.L., et al. Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. Clin Gastroenterol Hepatol 2010, 8:261-267. e1-4.
37. Knudsen A.B., Lansdorp-Vogelaar I., Rutter C.M., et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the Medicare population. J Natl Cancer Inst 2010, 102:1238-1252.
38. Malone D.C., Waters H.C., Van Den Bos J., et al. A claims-based Markov model for Crohn's disease. Aliment Pharmacol Ther 2010, 32:448-458.
39. Gregor J.C., McDonald J.W., Klar N., et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997, 3:265-276.